Ribavirin Therapy for Hepatitis E Virus-Induced Acute on Chronic Liver Failure: A Preliminary Report
Antiviral Therapy · 2012-08 · 17 (6) · 1091-1096
DOI: 10.3851/imp2317 ↗At a glance
Fallbericht in Antiviral Therapy, published online on 2012-08-01. Written by Rohit Goyal and 4 co-authors. Institution: Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India. Cited 75 times so far (Crossref); 19 references.
Abstract (original language)
Hepatitis E virus (HEV) is a common cause of acute on chronic liver failure (ACLF) in HEV hyperendemic regions with high mortality. Treatment for HEV-induced ACLF is currently not available. Recently, efficacy of ribavirin in genotype 3 chronic hepatitis E patients has been reported; however, whether ribavirin is effective in genotype 1 HEV infection is not yet known. The present study includes four patients with HEV-induced ACLF treated with ribavirin in a genotype 1 HEV hyperendemic region. Diagnosis of ACLF was made by conventional criteria and HEV as the cause of ACLF was confirmed by detection of HEV RNA by reverse transcriptase PCR. Ribavirin dose ranged from 200 to 600 mg/day and was used for a median duration of 12 (range 3–24) weeks. All patients had undetectable HEV in 3–8 weeks, survived and none had serious adverse effects. This preliminary observation from a single centre indicates that ribavirin may be an effective therapeutic agent for HEV-induced ACLF and a randomized control trial is needed to establish its efficacy.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.
Cite
APA
Goyal, R., Kumar, A., Panda, S. K., Paul, S. B., & Acharya, S. K. (2012). Ribavirin Therapy for Hepatitis E Virus-Induced Acute on Chronic Liver Failure: A Preliminary Report. Antiviral Therapy, 17(6), 1091-1096. https://doi.org/10.3851/imp2317
Vancouver
Goyal R, Kumar A, Panda SK, Paul SB, Acharya SK. Ribavirin Therapy for Hepatitis E Virus-Induced Acute on Chronic Liver Failure: A Preliminary Report. Antiviral Therapy. 2012;17(6):1091-1096. doi:10.3851/imp2317
BibTeX
@article{Goyal2012,
author = {Goyal, Rohit and Kumar, Ajay and Panda, Subrat K and Paul, Shashi B and Acharya, Subrat K},
title = {Ribavirin Therapy for Hepatitis E Virus-Induced Acute on Chronic Liver Failure: A Preliminary Report},
journal = {Antiviral Therapy},
year = {2012},
volume = {17},
number = {6},
pages = {1091--1096},
doi = {10.3851/imp2317}
}
EUVIMED